MA38322B1 - Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires - Google Patents

Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires

Info

Publication number
MA38322B1
MA38322B1 MA38322A MA38322A MA38322B1 MA 38322 B1 MA38322 B1 MA 38322B1 MA 38322 A MA38322 A MA 38322A MA 38322 A MA38322 A MA 38322A MA 38322 B1 MA38322 B1 MA 38322B1
Authority
MA
Morocco
Prior art keywords
antibodies
autoimmune
treatment
inflammatory disorders
relates
Prior art date
Application number
MA38322A
Other languages
English (en)
Other versions
MA38322A1 (fr
Inventor
Thomas Huber
Padova Franco Di
Jean-Michel Rondeau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50239702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38322(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38322A1 publication Critical patent/MA38322A1/fr
Publication of MA38322B1 publication Critical patent/MA38322B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)

Abstract

La présente invention concerne des anticorps et des protéines comprenant une partie de liaison à un antigène de ceux-ci qui se lient spécifiquement à la cytokine pro-inflammatoire il-17a. L'invention concerne plus particulièrement des anticorps et des protéines spécifiques qui sont des antagonistes d'il-17a (inhibent les activités d'il-17a et d'il-17af) et sont capables d'inhiber la production de cytokines induite par il-17a dans des essais
MA38322A 2013-02-08 2014-02-07 Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires MA38322B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361762406P 2013-02-08 2013-02-08
PCT/IB2014/058854 WO2014122613A1 (fr) 2013-02-08 2014-02-07 Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires

Publications (2)

Publication Number Publication Date
MA38322A1 MA38322A1 (fr) 2017-09-29
MA38322B1 true MA38322B1 (fr) 2018-09-28

Family

ID=50239702

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38322A MA38322B1 (fr) 2013-02-08 2014-02-07 Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires

Country Status (38)

Country Link
US (6) US9193788B2 (fr)
EP (3) EP2953969B1 (fr)
JP (2) JP6084708B2 (fr)
KR (1) KR101877109B1 (fr)
CN (1) CN105073775B (fr)
AP (1) AP2015008584A0 (fr)
AR (1) AR095193A1 (fr)
AU (1) AU2014213599C1 (fr)
BR (1) BR112015017338B1 (fr)
CA (2) CA3185317A1 (fr)
CL (1) CL2015001941A1 (fr)
CR (1) CR20150405A (fr)
CU (1) CU24300B1 (fr)
CY (1) CY1122322T1 (fr)
DK (1) DK2953969T3 (fr)
EA (1) EA031537B1 (fr)
ES (2) ES2758473T3 (fr)
GT (1) GT201500220A (fr)
HR (1) HRP20192076T1 (fr)
HU (1) HUE047119T2 (fr)
IL (1) IL240135B (fr)
JO (1) JO3785B1 (fr)
LT (1) LT2953969T (fr)
MA (1) MA38322B1 (fr)
MX (1) MX371052B (fr)
PE (1) PE20151290A1 (fr)
PH (1) PH12015501713B1 (fr)
PL (1) PL2953969T3 (fr)
PT (1) PT2953969T (fr)
RS (1) RS59625B1 (fr)
SG (1) SG11201505330QA (fr)
SI (1) SI2953969T1 (fr)
SV (1) SV2015005019A (fr)
TN (1) TN2015000309A1 (fr)
TW (1) TWI632159B (fr)
UA (1) UA117575C2 (fr)
UY (1) UY35315A (fr)
WO (1) WO2014122613A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
EP3142645A4 (fr) 2014-05-15 2017-12-27 Rani Therapeutics, LLC Compositions pharmaceutiques et procédés de fabrication de masses solides comprenant des polypeptides et/ou des protéines
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20170291939A1 (en) * 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016123329A2 (fr) * 2015-01-28 2016-08-04 Genentech, Inc. Marqueurs d'expression génique et traitement de la sclérose en plaques
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
CN106474470B (zh) * 2015-08-28 2020-05-22 江苏恒瑞医药股份有限公司 一种抗il-17a抗体的组合物
MY206805A (en) * 2015-10-27 2025-01-08 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
WO2017106656A1 (fr) 2015-12-17 2017-06-22 Novartis Ag Molécules d'anticorps anti-pd-1 et leurs utilisations
WO2017152102A2 (fr) 2016-03-04 2017-09-08 Alector Llc Anticorps anti-trem1 et leurs méthodes d'utilisation
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (fr) 2016-06-22 2017-12-28 Novartis Ag Méthodes de traitement du vitiligo à l'aide d'anticorps de l'interleukine-17 (il -17)
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
WO2018015880A1 (fr) 2016-07-19 2018-01-25 Novartis Ag Procédés de traitement du psoriasis de type en plaques d'apparition récente au moyen d'antagonistes de l'il-17
KR102329490B1 (ko) * 2016-09-14 2021-11-23 베이징 한미 파마슈티컬 컴퍼니 리미티드 Ｉｌ-１７ａ에 특이적으로 결합하는 항체 및 그의 기능성 단편
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (fr) 2017-03-03 2018-09-07 Novartis Ag Modification de la maladie du psoriasis suite à un traitement à long terme avec un antagoniste de l'il-17
CN110582512B (zh) * 2017-03-10 2022-08-30 苏州鑫康合生物医药科技有限公司 针对il-17a和il-17f二者的单克隆抗体及其用途
US10676522B2 (en) * 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
CN108359011B (zh) * 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
CN107522783B (zh) * 2017-09-30 2020-07-07 华博生物医药技术（上海）有限公司 一种抗白介素17a的抗体、其制备方法和应用
WO2019087133A1 (fr) 2017-11-02 2019-05-09 Novartis Ag Procédé de traitement d'une tendinopathie à l'aide de l'interleukine-17 (il-17)
KR102048475B1 (ko) * 2017-11-10 2019-11-26 주식회사 와이바이오로직스 IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
BR112020010579A2 (pt) 2017-11-30 2020-11-10 Novartis Ag receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
WO2019163945A1 (fr) 2018-02-22 2019-08-29 学校法人東海大学 Inhibiteur de l'activité de l'il-17a et son utilisation
CN112203685A (zh) * 2018-03-29 2021-01-08 瑞美德生物医药科技有限公司 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
US12110323B2 (en) 2018-05-17 2024-10-08 Jiangsu Qyuns Therapeutics Co., Ltd. Anti-human interleukin 17A monoclonal antibody and application thereof
CN108640991B (zh) * 2018-05-17 2019-09-27 江苏荃信生物医药有限公司 抗人白介素17a单克隆抗体及其应用
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
US20200376135A1 (en) * 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
GB201820165D0 (en) * 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
CN111303283A (zh) * 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
TWI874341B (zh) * 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (fr) 2019-01-31 2020-08-05 Numab Therapeutics AG Anticorps dirigés contre il-17a et leurs procédés d'utilisation
MY205369A (en) * 2019-07-26 2024-10-17 Sinocelltech Ltd Humanized anti-il17a antibody and use thereof
EP4006053A4 (fr) * 2019-07-30 2022-10-26 Jiangsu Hengrui Medicine Co., Ltd. Méthode de traitement d'une maladie auto-immune par un antagoniste de l'il-17
AU2020386669A1 (en) 2019-11-19 2022-06-02 Novartis Ag Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists
EP4069737A2 (fr) 2019-12-06 2022-10-12 Novartis AG Procédés de traitement de lichen plan à l'aide d'antagonistes de l'interleukine 17 (il-17)
GB201919061D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
BR112022012064A2 (pt) * 2019-12-20 2022-08-30 Anthos Therapeutics Inc Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico
BR112022026273A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Métodos de tratamento da doença ocular da tireoide e orbitopatia de graves usando antagonistas de interleucina-17 (il-17)
WO2022032592A1 (fr) * 2020-08-13 2022-02-17 Tsinghua University Interleukine-17d et cd93 utilisés en tant que nouvelle paire cytokine-récepteur dans le système immunitaire
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
WO2023035272A1 (fr) * 2021-09-13 2023-03-16 深圳华普药物研发有限公司 Anticorps anti-il17, son procédé de préparation et application associée
CN116496394B (zh) * 2022-01-26 2024-07-23 东莞市朋志生物科技有限公司 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒
CA3253618A1 (fr) 2022-05-16 2023-11-23 Novartis Ag Méthodes de traitement de l'artérite à cellules géantes à l'aide d'antagonistes de l'interleukine-17 (il-17)
EP4525914A1 (fr) 2022-05-18 2025-03-26 Novartis AG Procédés de traitement sélectif de la tendinopathie à l'aide d'antagonistes de l'interleukine-17 (il-17)
CA3267516A1 (fr) * 2022-09-12 2024-03-21 Albert Einstein College Of Medicine Anticorps monoclonaux dirigés contre l'arabinomannane (am), la groel2 et la lprg, et procédés d'utilisation
EP4393948A1 (fr) * 2022-12-28 2024-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Anticorps vhh thérapeutiques neutralisant de manière croisée les homodimères il-17a et il-17f et l'hétérodimère il-17af
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
CN118005785B (zh) * 2023-12-29 2024-10-22 北京贝来药业有限公司 用于疾病治疗的串联纳米抗体
IT202400002382A1 (it) 2024-02-05 2025-08-05 Nautilon S R L Sistema e metodo di mappatura per la creazione di una mappa digitale georeferenziata 1 di almeno un tratto di una rete per il convogliamento di liquidi in pressione, in particolare di reti idriche potabili e non potabili.
CN118206654B (zh) * 2024-03-05 2024-09-20 北京贝来药业有限公司 用于疾病治疗的新型抗体及其产品和应用

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
SE434680B (sv) 1983-01-21 1984-08-06 Karl Arne Lundblad Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0401384B1 (fr) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
EP1690934A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP1291360A1 (fr) 1991-12-13 2003-03-12 Xoma Corporation Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
CA2124967C (fr) 1991-12-17 2008-04-08 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (fr) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
CA2161351C (fr) 1993-04-26 2010-12-21 Nils Lonberg Animaux transgeniques, pouvant produire des anticorps heterologues
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (fr) 1997-05-21 1998-11-26 Biovation Limited Procede de production de proteines non immunogenes
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (fr) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
EP2322644A1 (fr) 2000-06-28 2011-05-18 GlycoFi, Inc. Procédé de production de glycoprotéines modifiées
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
EP1421203A4 (fr) 2001-05-17 2005-06-01 Diversa Corp Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20080019249A (ko) 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
EP3611266B1 (fr) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Arn contenant des nucléosides modifiées et leurs procédés d'utilisation
CN101326195B9 (zh) * 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
AU2007215012A1 (en) 2006-02-15 2007-08-23 Imclone Llc Antibody formulation
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20070218065A1 (en) * 2006-03-10 2007-09-20 Jaspers Stephen R Antibodies that bind both il-17a and il-17f and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
CA2660463C (fr) * 2006-08-11 2013-07-16 Schering Corporation Anticorps diriges contre l'il-17a
WO2008133684A1 (fr) 2007-04-27 2008-11-06 Zymogenetics, Inc. Anticorps qui se lient à la fois à il-17a et il-17f et leurs procédés d'utilisation
JP5581323B2 (ja) * 2008-09-29 2014-08-27 ロシュ グリクアート アクチェンゲゼルシャフト ヒトｉｌ１７に対する抗体およびその使用
EP2403531A4 (fr) * 2009-03-05 2013-02-27 Abbott Lab Protéines de liaison à il-17
CA2759848C (fr) 2009-05-05 2018-12-04 Novimmune S.A. Anticorps anti-il-17f et leurs methodes d'utilisation
WO2011053763A2 (fr) * 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Antagonistes de l'il-17a
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
WO2013090186A1 (fr) 2011-12-14 2013-06-20 modeRNA Therapeutics Acides nucléiques modifiés, et utilisations en soins de courte durée de ceux-ci
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags

Also Published As

Publication number Publication date
BR112015017338A8 (pt) 2019-11-12
CU24300B1 (es) 2017-12-08
EP2953969A1 (fr) 2015-12-16
JP2017018106A (ja) 2017-01-26
ES2758473T3 (es) 2020-05-05
CN105073775A (zh) 2015-11-18
HK1211604A1 (en) 2016-05-27
PH12015501713B1 (en) 2019-03-06
MA38322A1 (fr) 2017-09-29
JP2016508508A (ja) 2016-03-22
IL240135A0 (en) 2015-09-24
TN2015000309A1 (en) 2017-01-03
PH12015501713A1 (en) 2015-11-09
UA117575C2 (uk) 2018-08-27
CY1122322T1 (el) 2021-01-27
US10683349B2 (en) 2020-06-16
MX2015010248A (es) 2016-09-28
BR112015017338A2 (pt) 2017-07-11
EA201591462A1 (ru) 2015-12-30
EP4450086A2 (fr) 2024-10-23
CN105073775B (zh) 2019-03-19
DK2953969T3 (da) 2019-12-02
GT201500220A (es) 2016-03-01
EP3656786B1 (fr) 2024-08-28
WO2014122613A1 (fr) 2014-08-14
US9193788B2 (en) 2015-11-24
PL2953969T3 (pl) 2020-02-28
TW201431879A (zh) 2014-08-16
US9650439B2 (en) 2017-05-16
SI2953969T1 (sl) 2020-01-31
US20180194839A1 (en) 2018-07-12
AU2014213599B2 (en) 2017-02-09
AU2014213599C1 (en) 2017-09-07
JO3785B1 (ar) 2021-01-31
ES2997610T3 (en) 2025-02-17
EP4450086A3 (fr) 2025-04-16
US20160039928A1 (en) 2016-02-11
CA3185317A1 (fr) 2014-08-14
US20200299379A1 (en) 2020-09-24
SG11201505330QA (en) 2015-08-28
AU2014213599A1 (en) 2015-07-23
US20170198035A1 (en) 2017-07-13
EA031537B1 (ru) 2019-01-31
EP2953969B1 (fr) 2019-08-28
CL2015001941A1 (es) 2015-10-30
IL240135B (en) 2020-02-27
NZ709739A (en) 2020-11-27
UY35315A (es) 2014-09-30
CA2897682A1 (fr) 2014-08-14
US20150175692A1 (en) 2015-06-25
KR101877109B1 (ko) 2018-07-10
US9938342B2 (en) 2018-04-10
EP3656786A1 (fr) 2020-05-27
BR112015017338B1 (pt) 2022-11-29
KR20150113198A (ko) 2015-10-07
TWI632159B (zh) 2018-08-11
HUE047119T2 (hu) 2020-04-28
AP2015008584A0 (en) 2015-07-31
LT2953969T (lt) 2019-12-10
PT2953969T (pt) 2019-12-03
SV2015005019A (es) 2018-06-12
HRP20192076T1 (hr) 2020-02-07
CR20150405A (es) 2015-09-28
RS59625B1 (sr) 2020-01-31
US20250145703A1 (en) 2025-05-08
PE20151290A1 (es) 2015-09-17
JP6266710B2 (ja) 2018-01-24
JP6084708B2 (ja) 2017-02-22
MX371052B (es) 2020-01-14
AR095193A1 (es) 2015-09-30
CU20150079A7 (es) 2016-02-29
CA2897682C (fr) 2023-03-14
US12077580B2 (en) 2024-09-03

Similar Documents

Publication Publication Date Title
MA38322B1 (fr) Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
MA38498A1 (fr) Protéines de liaison anti-lag-3
EP4403570A3 (fr) Anticorps anti-il-33 et leurs utilisations
MA38413A1 (fr) Anticorps pan-elr+ cxc chimiokine
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
EA200870130A1 (ru) Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MX375426B (es) Direccionamiento de antagonistas de citocinas.
EP2953643A4 (fr) Anticorps cd47 n'induisant ni l'appauvrissement en globules rouges ni l'appauvrissement en plaquettes
EA201892440A1 (ru) Антитела к tl1a и их применения
EA201890078A1 (ru) Антитело
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
MA38478A1 (fr) Anticorps anti-pac1 humains
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MX380702B (es) Proteinas de union al antigeno del receptor de oncostatina m.
CR20190535A (es) Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
MA38161A1 (fr) Anticorps anti-bmp-6
EA201491957A1 (ru) Антитела к ccl2 для лечения склеродермии
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MA41016B1 (fr) Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20